49 results about "Staphylococcal infections" patented technology

The invention discloses a monoclonal antibody for resisting staphylococcus aureus iron ion regulatory surface determinant B protein and application of the monoclonal antibody. Amino acid of a structural domain recognized by the monoclonal antibody is shown as SEQ ID NO.1. The monoclonal antibody is generated by culturing a host cell of an expression vector, the generated monoclonal antibody is secreted into supernate, and the supernate is secreted into the staphylococcus aureus iron ion regulatory surface determinant B protein to obtain the staphylococcus aureus iron ion regulatory surface determinant B. The staphylococcus aureus iron ion regulatory surface determinant B protein. Purifying through a chromatography technology; the obtained antibody can be used for treating septicopyemia caused by staphylococcus aureus / MRSA infection, and has important significance in preventing and treating staphylococcus aureus infection.

The invention provides a recombinant chicken antibacterial peptide aiming at drug-resistant staphylococcus aureus, and belongs to the technical field of veterinarians. The recombinant chicken antibacterial peptide is expressed through genetic engineering recombinant escherichia coli. Three natural chicken antibacterial peptide active regions are fused, and two disulfide bonds are introduced to stabilize the structure of the recombinant chicken antibacterial peptide and enhance the affinity of the recombinant chicken antibacterial peptide to staphylococcus aureus outer membrane protein. The minimum inhibitory concentration of the recombinant chicken antibacterial peptide to the drug-resistant staphylococcus aureus is obviously lower than that of three natural chicken antibacterial peptides, and the formation of a biomembrane of a USA300 strain of the drug-resistant staphylococcus aureus can be thoroughly inhibited when the minimum inhibitory concentration is 8 mu g / mL. The recombinant chicken antibacterial peptide has a good antibacterial effect on different drug-resistant staphylococcus aureus separated from a chicken house, and can effectively solve the infection problem of the drug-resistant staphylococcus aureus in the chicken house.

The invention discloses an application of an Mxene-Mo4VC4 new member nano platform with light-enhanced peroxidase activity in treatment of methicillin-resistant staphylococcus aureus infection so as to promote healing of infected wounds, and belongs to the field of two-dimensional nano material catalyst antibacterial research. The single-layer Mo4VC4 nanosheet is synthesized on the basis of Mo4AlVC4-MXene through a hydrofluoric acid etching method. The Mo4VC4 nanosheet shows activity similar to peroxidase, and can locally catalyze low-concentration hydrogen peroxide and generate hydroxyl radicals toxic to bacteria, so that methicillin-resistant staphylococcus aureus is effectively killed, and a biological membrane is removed. In addition, high photo-thermal conversion efficiency and photo-thermal stability are shown under irradiation of near-infrared light with low concentration (50 mu g / mL). The similar peroxidase activity is obviously amplified by the temperature rise caused by the photothermal effect of the Mo4VC4 nanosheet. And finally, rapidly eliminating methicillin-resistant staphylococcus aureus in deep infection and accelerating abscess regression by adopting a satisfactory photo-thermal amplification peroxidase strategy.

The invention discloses an application of a small molecule compound DK419 in preparation of a drug for resisting staphylococcus infection, and the CAS number of the small molecule compound DK419 is 2102672-22-8; the staphylococcus comprises at least one of staphylococcus aureus, staphylococcus epidermidis, staphylococcus hominis, staphylococcus capitis and staphylococcus haemolyticus. According to the technical scheme, the novel medical application of DK419 is disclosed, DK419 has the effects of inhibiting growth of staphylococcus and killing staphylococcus aureus, the antibacterial effect is better than that of first-line antibiotic vancomycin, and the bactericidal effect is equal to that of vancomycin; the DK419 has the effect of efficiently removing a biofilm; the DK419 can play a role in resisting staphylococcus aureus infection in an in-vivo skin infection model.

The invention discloses application of fludarabine in treatment of methicillin-resistant staphylococcus aureus infection, and in an MRSA infected mouse model, it is verified that fludarabine can improve the survival rate of MRSA infected mice, reduce the MRSA bacterial count of lungs, livers, spleens and kidneys and relieve the injury degree of lungs, livers, spleens and kidneys caused by MRSA infection; pSMalpha3 is found to be an important virulence factor of MRSA, is closely related to high pathogenicity of MRSA, and can induce death of macrophages in a concentration-dependent manner, and fludarabine can significantly reduce cytotoxicity caused by PSMalpha3.

Provided herein are methods and systems for use in determining risk of a Staphylococcus infection, predicting efficacy of a Staphylococcus vaccine, and prognosing clinical outcomes on a subject exposed to Staphylococcus. Methods of treating subject identified as having or at risk of a Staphylococcus infection are further provided.

The invention discloses an application of a compound 5928-0054 in preparation of anti-staphylococcus aureus hemolysin medicines, and belongs to the field of microbial infectious diseases and medicines. The invention finds that the compound 5928-0054 can neutralize the toxicity of staphylococcus aureus hemolysin, has a protection effect on mice infected by MRSA staphylococcus aureus USA300, and has the application of preparing the anti-staphylococcus aureus hemolysin medicine and the medicine for preventing or treating staphylococcus aureus infection. The new medicinal value of the compound 5928-0054 is found, and a new medicine for preventing and treating staphylococcus aureus infection is provided; the compound 5928-0054 can neutralize the main virulence factor of staphylococcus aureus, namely hemolysin, so that inflammatory injury is relieved.

The invention relates to the field of antibacterial polypeptides, specifically to the field of antibacterial polypeptides having lytic activity for Staphylococcus. The invention relates to a novel chimeric endolysin polypeptide specifically targeting a Staphylococcus cell. The invention further relates to the use of said chimeric endolysin polypeptide as a disinfectant, as an antimicrobial cosmetic, for detection, such as in a diagnostic application and for medical use, such as for treating an individual suffering from a condition associated with a Staphylococcus infection.

The invention belongs to the technical field of biological medicine, and particularly relates to a PDHC mutant, an immunogenic fragment and application, the PDHC mutant has amino acid mutation at at least one of the 214th site, the 274th site or the 294th site of the amino acid sequence shown in SEQ ID NO: 1, and the PDHC mutant is used for preventing or treating staphylococcus aureus (SA) infection and is an mRNA vaccine for preventing or treating staphylococcus aureus (SA) infection. The stability and immunogenicity of the staphylococcus aureus PDHC antigen are greatly improved, efficient targeted delivery of the antigen is achieved, and the immune effect of the vaccine is remarkably improved.

The application discloses an antibody against Staphylococcus aureus IsdB and application thereof. The antibody comprises a heavy chain variable region and a light chain variable region, the amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain variable region are respectively shown as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain variable region are respectively shown as SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11. In addition, the application further discloses a product for detecting Staphylococcus aureus IsdB and application of the antibody in preparation of a diagnosis, prevention and / or treatment of diseases related to Staphylococcus aureus infection. The application provides a new idea for detection of Staphylococcus aureus IsdB and treatment of related diseases, and has a wide application prospect.

Lipid-based drug delivery vehicles (including liposomal nanoparticles) are described which include antibiotic(s) for the treatment of infections, such as Methicillin-Resistant Staphylococcus (S.) aureus (MRSA) infections and Methicillin-Susceptible S. aureus (MSSA) infections. These drug delivery vehicles have high drug-loading, do not accumulate in the liver, and can optionally include one or more targeting ligands.

Unglycosylated lysostaphin variant protein, nucleic acid molecule, vector and host cell, as well as a method for production of unglycosylated lysostaphin variant protein in a yeast expression system are provided. The proteins are produced in a Pichia pastoris expression system and have been shown to have activity equivalent to wild-type lysostaphin. The lysostaphin variant proteins can be used as therapeutic proteins for treatment of diseases such as Staphylococcus aureus infection.

The invention discloses an application of a hexagonal copper sulfide nano-platform with photo-thermal enhanced peroxidase activity in treatment of methicillin-resistant staphylococcus aureus infection so as to promote healing of infected wounds. An improved one-pot method is adopted to synthesize a hexagonal copper sulfide nano-sheet. Due to the fact that the hexagonal copper sulfide nanosheet shows good photothermal conversion efficiency and photothermal stability in a second near-infrared window and further shows excellent peroxidase-like activity, temperature rise caused by the photothermal effect of the hexagonal copper sulfide nanosheet remarkably amplifies the peroxidase-like activity of the hexagonal copper sulfide nanosheet. The hexagonal copper sulfide nanosheet plays a good biological catalytic antibacterial role in vitro, under photo-thermal irradiation, abscess fading and healing of in-vivo methicillin-resistant staphylococcus aureus infected wounds are promoted, and toxicity can be ignored. The copper sulfide nanosheet provides a feasible strategy for effectively treating a deep methicillin-resistant staphylococcus aureus infected wound by utilizing a synergistic treatment platform.

Embodiments relate to methods and compositions for preventing or treating bacterial infections, particularly Staphylococcal infections. Embodiments relate to improved non-toxigenic protein A (SpA) variants.

Provided herein are compounds, derivatives thereof, composition comprising one or more of said compounds and derivatives, and methods for prevention and / or treatment of microbial infections and / or related diseases or conditions. The present compounds and / or derivatives thereof can be represented by Formula (II):The present methods include administering to a subject an effective amount of one or more compounds of Formula (II). In one embodiment, said microbial infections are bacterial infections. More specifically, the bacterial infections are staphylococcal infections. Compositions are provided that include compounds of formula II in combination with one or more antibiotics or one or more staphyloxanthin-synthesis-inhibiting compounds.

This application relates to the field of biotechnology, and specifically discloses a kit for detecting intracranial Staphylococcus infection and its application. The kit substrate includes a fluorescent substance containing an NHS ester reaction group and a glycopeptide antibiotic; its preparation method is as follows: the fluorescent substance containing an NHS ester reaction group and the glycopeptide antibiotic are respectively dissolved in DMSO solution; after dissolution is complete, the two are stirred and mixed to obtain a mixture; the stirred mixture is purified to obtain a fluorescent substance-glycopeptide antibiotic fluorescent targeting probe, and the fluorescent substance-glycopeptide antibiotic fluorescent targeting probe is the kit substrate. The kit substrate of this application has strong specificity, and the generated fluorescent substance-glycopeptide antibiotic fluorescent targeting probe can be used to specifically identify intracranial Staphylococcus infection.

The present invention discloses a Bacillus cereus aminomethyltransferase antimicrobial peptide BA14, whose amino acid sequence is HKKEMVLAWLQNQK, and the molecular weight of the antimicrobial peptide is 1753.092 Daltons. The antimicrobial peptide of the present invention has a significant inhibitory effect on Staphylococcus aureus, and can be used as a medicine or feed additive for preparing a drug for preventing or inhibiting Staphylococcus aureus infection. Studies have shown that the antimicrobial peptide BA14 of the present invention combined with vitamin D3 can kill or strongly inhibit the growth of Staphylococcus aureus.

The present invention discloses a fully human SEB monoclonal antibody against Staphylococcus aureus enterotoxin B and its applications. The amino acid sequences of CDR1, CDR2, and CDR3 in the variable region of the heavy chain of the antibody are shown as SEQ ID NO.5, SEQ ID NO.6, and SEQ ID NO.7 respectively; the amino acid sequences of CDR1, CDR2, and CDR3 in the variable region of the light chain are shown as SEQ ID NO.9, SEQ ID NO.10, and SEQ ID NO.11 respectively; the antibody can specifically bind to Staphylococcus aureus enterotoxin B and can be used for the treatment, prevention, or diagnosis of Staphylococcus aureus infections and toxic shock syndrome caused by enterotoxin B, which will become an important direction in the research field of "non-antibiotic" treatment of drug-resistant Staphylococcus aureus infections and control of the development of drug resistance.

Cannabinoid analogs disclosed herein may exhibit antibacterial and anti-inflammatory properties. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) infections, as well as various disorders associated with chronic inflammation, such as arthritis. In some aspects, a pharmaceutical composition may be administered to an individual who has been exposed or is at risk of exposure to Bacillus anthracis or Bacillus anthracis spores.

The invention discloses an application of a photostable pyridine fused Norcorrole nickel (II) dimer in treatment of staphylococcus aureus infection, and belongs to the technical field of medicines. The efficient antibacterial performance of the anti-aromaticity compound Ni (II)-PyNc2 under NIR irradiation is proved, the PCE of the anti-aromaticity compound Ni (II)-PyNc2 reaches 73%, and the temperature rises to 56 DEG C after the anti-aromaticity compound Ni (II)-PyNc2 is irradiated for 6 minutes. Through in-vitro and in-vivo experiments, Ni (II)-PyNc2 shows excellent light stability, biological membrane inhibition capability and wound healing promotion effect, and has good biocompatibility. The material is expected to become an ideal candidate for clinical photo-thermal therapy.

The invention discloses a manganese-based nano-enzyme preparation method, a manganese-based nano-enzyme product and an application of the manganese-based nano-enzyme product in antibiosis, and belongs to the technical field of nano-enzymes and biomedicine nanotechnology. According to the preparation method, KMnO4 and C18H34O2 are used as raw materials, and the manganese-based nano-enzyme is prepared through a water phase method. The nano-enzyme shows good application prospects in removing bacterial biofilms, inhibiting bacteria from forming biofilms and treating wound infection models. Animal experiments show that the hydrogel has excellent biocompatibility, is free of toxic accumulation, and can effectively treat mouse wound staphylococcus aureus infection and promote wound healing.

The invention discloses an antigen protein as well as a preparation method and application thereof. The antigen protein comprises a soluble catalytic domain of the membrane protein LCP or a variant thereof. The antigen protein can be used for preventing and treating staphylococcus aureus infection, especially drug-resistant bacteria infection, and clinical related infectious diseases caused by the staphylococcus aureus infection, so that more stable broad-spectrum protection on staphylococcus aureus infection, especially drug-resistant staphylococcus aureus, is realized.

The application provides a staphylococcus aureus toxin LukG antigen epitope peptide, comprising a polypeptide with an amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 40 or SEQ ID NO: 42, and the application also provides application of the antigen epitope peptide in preparation of a staphylococcus aureus infection diagnostic, preventive or therapeutic product. The application determines a staphylococcus aureus toxin LukG antibody dominant epitope peptide through screening, and the staphylococcus aureus toxin LukG antibody dominant epitope peptide has strong immunogenicity and can be used for staphylococcus aureus infection diagnosis, prevention or treatment.

The present application relates to the application of Staphylococcus aureus toxin protein related gene SA1833 / SA1832 in treating Staphylococcus aureus infection. Specifically, it relates to the application of Staphylococcus aureus toxin protein related gene SA1833 and / or SA1832 as a target in the preparation of a drug for treating drug-resistant Staphylococcus aureus infection, preferably, the drug resistance is preferably methicillin resistance. With SA1833 and / or SA1832 as a target, the clinical treatment of repeated and persistent infection caused by methicillin-resistant Staphylococcus aureus retention has a significant effect. It provides a new target for the development of drugs for treating repeated infection caused by clinical MRSA strains, provides more choices for the treatment of Staphylococcus aureus, and has a wide application prospect.

The current disclosure provides novel compositions for treating bacterial infections. Accordingly, aspects of the disclosure relate to an engineered antibody comprising: LCDR1, LCDR2, and LCDR3 of the light chain variable region of the 3F6 antibody and HCDR1, HCDR2, and HCDR3 of the heavy chain variable region of the 3F6 antibody. Also provided are compositions comprising the antibodies and nucleic acids encoding either the heavy chain or light chain (or both) of the antibodies. Other aspects relate to host cells comprising the antibodies and / or nucleic acids of the disclosure. Further aspects relate to a method of preventing or treating staphylococcal infection comprising the step of administering the antibody of the disclosure to a subject in need thereof. Yet further aspects relate to a method of making the antibody comprising expressing the nucleic acid(s) of the disclosure in a cell and isolating the expressed protein.

The invention discloses a Bacillus cereus 2,3-diphosphoglycerate mutase antimicrobial peptide BM16, whose amino acid sequence is HSHMNHMFALLRLAAK, and the molecular weight of the antimicrobial peptide is 1877.27 Daltons. The antimicrobial peptide of the invention has a significant inhibitory effect on hemolytic Staphylococcus aureus, and can be used as a drug for preparing a drug for preventing or inhibiting hemolytic Staphylococcus aureus infection.

The application provides a recombinant chicken antibacterial peptide against drug-resistant Staphylococcus aureus and belongs to the field of veterinary technology. The recombinant chicken antibacterial peptide is expressed by genetically engineering recombinant Escherichia coli. Three active regions of natural chicken antibacterial peptides are fused, and two disulfide bonds are introduced to stabilize the structure of the recombinant chicken antibacterial peptide and enhance the affinity of the recombinant chicken antibacterial peptide to the outer membrane protein of Staphylococcus aureus. The minimum inhibitory concentration of the recombinant chicken antibacterial peptide to drug-resistant Staphylococcus aureus is significantly lower than that of the three natural chicken antibacterial peptides, and the minimum inhibitory concentration of 8 μg / mL can completely inhibit the formation of a biological membrane of a drug-resistant Staphylococcus aureus USA300 strain. The recombinant chicken antibacterial peptide has good antibacterial effect on different drug-resistant Staphylococcus aureus isolated from a chicken farm, and can effectively solve the problem of drug-resistant Staphylococcus aureus infection in the chicken farm.

The invention provides a staphylococcus aureus toxin LukG antigen epitope peptide, which comprises a polypeptide with an amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 40 or SEQ ID NO: 42, and also provides an application of the antigen epitope peptide in preparation of drugs for diagnosing, preventing or treating staphylococcus aureus infection. The antibody dominant epitope peptide of the staphylococcus aureus toxin LukG is determined through screening, and the antibody dominant epitope peptide has high immunogenicity and can be used for diagnosis, prevention or treatment of staphylococcus aureus infection.

The invention relates to an antivirulence agent having an indolidone group and a use thereof. More specifically, the present invention relates to an antivirulence agent against Staphylococcus aureus, the agent being a compound having an indolidone group, and a pharmaceutical composition for treating Staphylococcus aureus infection. The compound having an indolidone group according to the present invention has excellent antivirulence activity that inhibits bacterial virulence without inducing bacterial resistance, and thus can be effectively used as an antivirulence agent for bacteria and a therapeutic agent for bacterial infections.

The present invention relates to the field of medicine, in particular to the treatment of conditions associated with Staphylococcus infection. The invention relates to a novel endolysin polypeptide specifically targeting bacterial staphylococcus cells. The invention further relates to said endolysin polypeptide for medical use, preferably for treating an individual suffering from a condition associated with a Staphylococcus infection.